Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research

Table 2

Characteristics and changes in patients with HBV reactivation and those without HBV reactivation.

Characteristics	HBV reactivation (n = 42)	No reactivation (n = 66)	t or χ^2	value
Gender			0.230	0.632
Male	28	41
Female	14	25
Age (years)	57.40 ± 9.59	59.51 ± 10.6	−1.046	0.298
Child-Pugh grade			2.256	0.133
A	24	47
B	18	19
HBeAg			2.494	0.114
Positive	25	29
Negative	17	37
Liver cirrhosis			2.693	0.101
Yes	20	42
No	22	24
HBV DNA before TACE (copies/mL)			17.852	<0.001
≥10^4	25	13
<10^4	17	53
Number of nodules			1.299	0.255
Single	29	52
Multiple	13	14
Tumor diameter (cm)	6.83 ± 2.12	6.65 ± 2.07	0.441	0.660
PVTT			0.003	0.959
Yes	10	16
No	32	50
AFP before TACE (ng/mL)	463.78 ± 251.57	430.44 ± 254.21	0.667	0.506
AFP after TACE (ng/mL)	333.90 ± 200.31	244.89 ± 174.47	2.435	0.017
T cells before TACE
CD3+ (%)	55.77 ± 9.72	55.10 ± 8.17	0.387	0.700
CD4+ (%)	26.82 ± 4.63	26.76 ± 4.12	0.068	0.946
CD4+/CD8+	0.94 ± 0.11	0.96 ± 0.14	–0.905	0.367
T cells after TACE
CD3+ (%)	48.57 ± 6.28	51.97 ± 5.40	−2.992	0.003
CD4+ (%)	20.91 ± 3.33	23.95 ± 3.30	−4.638	<0.001
CD4+/CD8+	0.72 ± 0.11	0.86 ± 0.13	−2.393	0.018

AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization; HBeAg, hepatitis B e antigen.